New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA : vimarsana.com

/PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the...

Related Keywords

China , United States , Chinese , Xia Yu , Kong Beihua , Wu Xiaohua , Department Of Obstetrics , Chinese Medical Association Gynecological Oncology Branch , Akeso Inc , Qilu Hospital Of Shandong University , Prnewswire Akeso Inc , National Medical Products Administration , Drug Administration Of The United States , Fudan University Cancer Hospital , Global Strategy , Cervical Cancer , Healthy China , Qilu Hospital , Shandong University , Drug Administration , Drug Evaluation , சீனா , ஒன்றுபட்டது மாநிலங்களில் , சீன , கிஷிய யூ , துறை ஆஃப் மகப்பேறியல் , உலகளாவிய மூலோபாயம் , ஆரோக்கியமான சீனா , சாண்டோங் பல்கலைக்கழகம் , மருந்து மதிப்பீடு , Akeso , Nc , Pharmaceuticals , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , International Medical Approval ,